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Abstract
Background: Ventilator-associated event (VAE) is a new surveillance paradigm for monitoring complications in
mechanically ventilated patients in intensive care units (ICUs). The National Healthcare Safety Network replaced
traditional ventilator-associated pneumonia (VAP) surveillance with VAE surveillance in 2013. The objective of this
study was to assess the consistency between VAE surveillance and traditional VAP surveillance.
Methods: We systematically searched electronic reference databases for articles describing VAE and VAP in ICUs.
Pooled VAE prevalence, pooled estimates (sensitivity, specificity, positive predictive value (PPV), and negative
predictive value (NPV)) of VAE for the detection of VAP, and pooled estimates (weighted mean difference (WMD)
and odds ratio ([OR)) of risk factors for VAE compared to VAP were calculated.
Results: From 2191 screened titles, 18 articles met our inclusion criteria, representing 61,489 patients receiving
mechanical ventilation at ICUs in eight countries. The pooled prevalence rates of ventilator-associated conditions
(VAC), infection-related VAC (IVAC), possible VAP, probable VAP, and traditional VAP were 13.8 %, 6.4 %, 1.1 %, 0.9 %,
and 11.9 %, respectively. Pooled sensitivity and PPV of each VAE type for VAP detection did not exceed 50 %, while
pooled specificity and NPV exceeded 80 %. Compared with VAP, pooled ORs of in-hospital death were 1.49 for VAC
and 1.76 for IVAC; pooled WMDs of hospital length of stay were −4.27 days for VAC and −5.86 days for IVAC; and
pooled WMDs of ventilation duration were −2.79 days for VAC and −2.89 days for IVAC.
Conclusions: VAE surveillance missed many cases of VAP, and the population characteristics identified by the two
surveillance paradigms differed. VAE surveillance does not accurately detect cases of traditional VAP in ICUs.
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Background
Mechanical ventilation (MV) is a widely used interven-
tion for critically ill patients in intensive care units
(ICUs). Ventilator-associated pneumonia (VAP) is a clin-
ically important, potentially preventable complication of
mechanical ventilation [1–3].
Prior to 2013, the National Healthcare Safety Network
(NHSN) monitored MV complications by VAP
surveillance. The clinical diagnosis of VAP is based on
clinical signs, chest radiography, and microbiological
data. Clinical signs include: changes in sputum or
tracheal secretions in terms of purulence, color, and/or in-
creasing production; cough; temperature >38 or <36 °C;
rales or bronchial breath sounds on examination, and
worsening oxygenation. Laboratory findings include
non-specific indicators of infection including
leukocytosis (>12 × 109 white blood cells (WBC)/L)
or leukopenia (<4.0 × 109 WBC/L). Signs on chest
radiography include the development of new infil-
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However, VAP surveillance relying on clinical criteria
has proven highly problematic in practice, because most
of these diagnostic criteria are not objective or specific
[5–7], leaving a wide margin in the surveillance of infec-
tion for subjective diagnosis of VAP. Under strong pres-
sure on hospitals to minimize VAP, these subjective
criteria have been applied with increasing stringency,
resulting in progressively lower prevalence of VAP.
Indeed, previous NHSN reports indicate zero prevalence
of VAP in more than 50 % of non-teaching ICUs in the
USA [8, 9]. To a certain extent, this decrease reflects
artifacts of VAP surveillance methods rather than true
improvements in care [10].
As VAP surveillance has limited accuracy, the Centers
for Disease Control (CDC) recommended a new surveil-
lance paradigm based on ventilation-associated events
(VAE) to assess complications in patients receiving MV.
The ventilator-associated event paradigm includes a
hierarchy of surveillance targets - ventilation-associated
condition (VAC), infection-related ventilated-associated
condition (IVAC), and possible and probable VAP. VAC
is defined as at least two calendar days of stable or de-
creasing daily minimum positive end-expiratory pressure
(PEEP) or daily minimum fraction of inspired oxygen
(FiO2) followed by an increase in daily minimum PEEP
by at least 3 cm H2O sustained for at least two calendar
days or an increase in daily minimum FiO2 by at least 20
points sustained for at least two calendar days. IVAC is
the subset of VAC that may be infection-related based
on concurrent inflammatory signs and at least 4 days of
new antibiotics. Possible VAP requires either Gram stain
evidence of purulence or a pathogenic culture; probable
pneumonia requires Gram stain evidence of purulence
and quantitative or semi-quantitative growth of a patho-
genic organism beyond defined thresholds [11].
The VAE paradigm broadens the focus of surveillance
beyond the infectious etiology of respiratory failure to
other physiological changes associated with suboptimal
ventilator care or progression of underlying diseases,
such as pulmonary edema, acute respiratory distress syn-
drome (ARDS), atelectasis, mucus plugging, pulmonary
embolus, and radiation pneumonitis [12].
The NHSN replaced VAP surveillance with VAE
surveillance in 2013, because the VAE paradigm makes
surveillance more objective to facilitate automation and
comparability [10]. Although VAE surveillance shifts the
focus away from pneumonia and toward common com-
plications that occur in critically ill patients receiving
mechanical ventilation, VAP continues to play a major
role in morbidity and length of stay (LOS) and is an im-
portant component of VAE. However, whether there are
differences between VAP identified by the new VAE
surveillance method compared with conventional VAP
surveillance remains controversial. Some researchers
report good correlation between the two surveillance
paradigms [13], while others have claim that VAE sur-
veillance does not accurately reflect VAP [14, 15].
Understanding the difference between VAE and VAP
surveillance is valuable, because the change of surveil-
lance paradigm may ultimately affect strategies for VAP
prevention and control. Accordingly, we conducted a
systematic review and meta-analysis of studies reporting
consistency between VAE and VAP. Our objectives were
primarily to quantitatively determine the consistency of
VAP identification between the two surveillance para-
digms, and secondarily to explore the differences in




We electronically searched literature that reported
prevalence of or risk factors for VAE in the PubMed,
EMBASE, ScienceDirect, and Cochrane Database on 2
February 2016 for original articles published after 1
January 2010 in peer-reviewed journals. Relevant articles
were identified according to the following Boolean ex-
pression: (ventilator-associated events [Title/Abstract]
OR ventilator-associated conditions [Title/Abstract] OR
ventilator-associated complications [Title/Abstract])
AND (prevalence [Mesh] OR risk factors [Mesh]). A ref-
erence list of key reviews was also searched for add-
itional studies.
Selection criteria
Studies that assessed VAE, including VAC, IVAC, pos-
sible VAP, and probable VAP, among adult patients who
received mechanical ventilation in an ICU were included
in our meta-analysis. We included eligible studies that
met at least one of the following criteria:
1. Studies providing original data that could be used to
calculate the prevalence rate of VAE, odds ratio
(OR), or weighted mean difference (WMD) of risk
factors for VAE compared to VAP.
2. Studies reporting VAE and VAP in the same
population that could be used to calculate relevant
indicators of VAE surveillance for the detection of
VAP (sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV).
Studies of paediatric patients or patients from the
emergency department were excluded in our analysis.
Conference proceedings, reviews, editorials, commentar-
ies, letters and publications in abstract form only were
also excluded. In the case of duplicate studies involving
the same subject, we chose the most recent one study.
Fan et al. Critical Care  (2016) 20:338 Page 2 of 13
Study identification
All titles and abstracts of the citations that were gener-
ated by the literature search were screened independ-
ently by two reviewers. Relevant publications were
reviewed in their entirety, and the reviewers were
blinded to the author and research institution of each
study. Each reviewer made a judgment on the inclusion
or exclusion of the study. In the event of disagreement, a
third reviewer served as a consultant to resolve the
issue.
Data extraction
For each included report, the following data were ex-
tracted: publication date, region, population, baseline
period, hospital, type of ICU, prevalence of VAE with
number of cases (n) or corresponding denominators (N),
and risk factors (including age, gender, the acute physi-
ology and chronic health evaluation (APACHE) score,
hospital length of stay, ICU length of stay, duration of
ventilation, in-hospital mortality, and ICU mortality).
Quality assessment
The quality of the studies was assessed independently,
using the Newcastle–Otawa scale (NOS) for non-
randomised observational studies [16], while the Jadad
scale was used for randomised controlled trials (RCTs)
[17]. The NOS scale allocates a maximum of nine stars
to a study, judged on three broad perspectives: the selec-
tion of the study groups; the comparability of the
groups; and the ascertainment of either the exposure or
outcome of interest for case–control or cohort studies,
respectively. Studies were defined as poor (0–3), fair (4–
6), or good (7–9). The Jadad scale assesses the quality of
RCTs relevant to random assignment, double-blinding,
and the flow of patients. It allocates a maximum of 5
points to a study. Studies were defined as poor (0–1),
fair (2–3), or good (4–5). Two assessors independently
evaluated the methodological quality of included studies,
and disagreement was resolved through discussion with
a third assessor.
Outcome measures
The primary outcomes were pooled prevalence rate and
pooled consistency between VAE and VAP (sensitivity,
specificity, PPV, and NPV). The secondary outcomes
were pooled ORs and WMDs of relevant factors for
VAE compared with VAP (age, sex, APACHE score,
LOS, ventilation duration, and mortality). The meta-
analysis comparison between VAE and VAP was limited
to studies that reported VAE and VAP simultaneously.
Studies that reported VAE only were not included in the
comparison analysis but were included in the prevalence
analysis. In the comparison analysis, continuous data
were expressed as WMD and dichotomous data as OR.
Statistical analyses
A random effects model was used to calculate pooled es-
timates and their 95 % confidence intervals (CIs) if there
was significant heterogeneity among studies. Otherwise,
a fixed effects model was chosen. The VAP detection
capability was assessed by receiver operating characteris-
tic (ROC) curves. A ROC curve was plotted using the
sensitivity and 1− specificity of each study that reported
original data. Heterogeneity was assessed by the Q test
and I2 statistic. Egger’s test was used to estimate publica-
tion bias in meta-analyses containing more than two
individual studies.
Sensitivity analysis was performed by limiting the
meta-analysis to studies that used the standard CDC/
NHSN definition of VAE for diagnosing VAE and the
CDC/NHSN criteria for VAP with quantitative culture
results in the diagnosis of VAP, in order to test the im-
pact of the diagnosis method on the pooled results. All
tests were two-tailed and statistical significance was
defined by a p value <0.05. All analyses were conducted
using STATA software (version 11.0, Stata corp., College
Station, TX, USA). The study was reviewed and
approved by the ethical committee of Union Hospital,
Tongji Medical College, Huazhong University of Science
and Technology.
Results
Our search identified 2192 publications. A flow diagram
of the selection process is presented in Fig. 1. A total of
888 duplicate publications were removed, and of the
remaining 1304 original articles, 1237 were excluded as ir-
relevant to the study objectives based on their titles and
abstracts. Two authors independently reviewed 67 full-
text articles and excluded 49 articles that did not meet the
selection criteria. Ultimately, 18 studies [18–35] (12 co-
hort studies, 2 nested case–control studies, 2 time-series
analysis studies, 1 screening test, and 1 RCT) were
selected for final analysis. One study reported a group of
patients from collaborative units undergoing daily spon-
taneous awakening and spontaneous breathing trials and a
group of patients from surveillance-only units [18], and
another study reported a group of patients undergoing
subglottic secretion suctioning and a group of patients not
having subglottic secretion suctioning [19]. For the pur-
pose of our analysis, these groups were treated as four
separate studies. Table 1 presents a list of the included
studies and their characteristics. In all, the meta-analysis
included 61,489 patients who received mechanical ventila-
tion in ICUs in eight countries. Most studies were of
acceptable quality, apart from one that was rated as poor
(Additional file 1: Table S1).
The pooled prevalence rates of each type of VAE
and VAP are shown in Table 2. Among mechanically
ventilated patients, the pooled prevalence of VAC
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(13.8 %, 95 % CI 9.0, 18.6 %) was higher, and that of
IVAC (6.4 %, 95 % CI 4.8, 8.1 %) lower, than that of
VAP (11.9 %, 95 % CI 9.4, 14.4 %). VAE surveillance
detected fewer cases of possible and probable VAP
among ventilated patients, with pooled prevalence
rates of 1.1 % (95 % CI 0.5, 1.7 %) and 0.9 % (95 %
CI 0.6, 1.2 %), respectively. Additionally, the pooled
prevalence of VAE and VAP increased with the pro-
longation of ventilation.
In consistency analysis of VAE and VAP, pooled sensi-
tivity was the highest for VAC at 41.8 % (95 % CI 17.7,
65.9 %) and lowest for probable VAP at 1.6 % (95 % CI
0.1, 3.2 %). Pooled PPV was the highest for IVAC at 47.2
% (95 % CI 16.1, 78.3 %) and lowest for probable VAP at
6.5 % (95 % CI 0.3, 12.6 %). Overall, the pooled estimates
of sensitivity and PPV of each VAE type for the detection
of VAP did not exceed 50 %. By contrast, the pooled
specificity and NPV of VAC and IVAC were greater than
80 %, and those of possible VAP and probable VAP were
nearly 100 % (Table 3). The ROC curve for IVAC
showed a better capability of VAP detection compared
with that of VAC (Fig. 2). ROC curves for possible and
probable VAP were not plotted, because studies that
provided original sensitivity and specificity data were
scarce.
The results of comparisons of population characteris-
tics between VAE and VAP surveillance are shown in
Table 4. In-hospital mortality in VAE was higher than
that of VAP: the pooled OR of death in hospital was
1.49 (95 % CI 1.11, 2.01) for VAC and 1.76 (95 % CI
1.23, 2.52) for IVAC. Hospital LOS was shorter for VAE
compared to VAP: the pooled WMD of hospital LOS
was −4.27 days (95 % CI −7.00, −1.55 days) for VAC and
−5.86 days (95 % CI −9.46, −2.25 days) for IVAC. Add-
itionally, compared with VAP, the pooled WMD of
ventilation duration was −2.79 days (95 % CI −4.79,
−0.80 days) for VAC and −2.89 days (95 % CI −5.58,
−0.20 days) for IVAC. On the other hand, VAE and
VAP did not significantly differ by age, sex, APACHE
score, or ICU LOS.
In sensitivity analysis, limiting the meta-analysis to
studies that employed the standard CDC/NHSN criteria
for VAE [18–21, 23–32, 35] and definite VAP identified
by quantitative culture of specimens from patients [19,
21, 24, 28, 35], the pooled estimates were robust except
for pooled prevalence (Additional file 1: Tables S2–S4).
The pooled prevalence rates of each VAE type de-
creased but VAP increased after limiting the analyses
to these studies. The new pooled prevalence of VAC
(8.0 %, 95 % CI 6.5, 9.6 %) and IVAC (4.0 %, 95 % CI
3.1, 4.9 %) were lower than that of VAP (13.0 %, 95
% CI 6.3, 19.7 %).
Among all meta-analyses containing more than two
individual studies, publication bias was detected only for
Fig. 1 Flow diagram of the selection process
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Table 1 Characteristics of studies included in the meta-analysis
Reference Region Units (n) ICU type Baseline
period
Population VAE criteria VAP criteria Design Sample size Adjusted confounders
Total (n) VAE VAP









CDC/NHSN definition NA Interrupted time
series analysis
3425 293 NA Age, sex, reason for
intubation, and SOFA
score









CDC/NHSN definition NA Interrupted time
series analysis
1739 75 NA Age, sex, reason for
intubation, and SOFA
score
[18]a Belgium 1 ICU 2012.01–
2013.03
Adult patients ventilated










170 37 15 NA
[18]b Belgium 1 ICU 2012.01–
2013.03
Adult patients ventilated










182 41 32 NA
[19] China 1 ICU 2010.04–
2014.02
VAP patients CDC/NHSN definition CDC/NHSN criteria Retrospective
cohort
165 55 165 NA
[20] USA 1 SICU, MICU 2013.01–
2013.12
Adult patients ventilated
for ≥2 calendar days















(≥2 day rise in range
of PEEP or a
decreasing PaO2/FiO2
ratio by >50 mm Hg
with the same level




CDC/NHSN criteria Inception cohort 3028 2331 816 NA




CDC/NHSN definition NA Retrospective
cohort
257 19 NA NA




















Table 1 Characteristics of studies included in the meta-analysis (Continued)
[24] USA 1 MICU, SICU 2008.07–
2013.03
Adult patients ventilated
for ≥4 calendar days
continuously
CDC/NHSN definition CDC/NHSN criteria Retrospective
cohort
3302 675 30c Race, comorbidities,
emergent admissions








CDC/NHSN definition CDC/NHSN criteria Prospective
cohort
8408 387 83 APACHE score, type
of ICU







CDC/NHSN definition NA Retrospective
nested case–
control
2990 172 NA Age, sex, ICU type,
Charlson score, and
time to VAC onset
[27] Netherland 2 ICU 2011.01–
2012.07









2080 152 3 Age, sex, APACHE
score, admission type,
and hospital
[28] England 1 ICU 2006.07–
2013.12
All episodes of invasive
mechanical ventilation
lasting ≥3 calendar days
CDC/NHSN definition NA Retrospective
cohort













CDC/NHSN definition NA Retrospective
cohort
20356 1056 NA Age, sex, unit type,
Charlson score, use
of vasopressors on





[30] Canada 1 ICU 2011.07–
2012.09
VAP patients received
at least 72 h broad-
spectrum antimicrobials
CDC/NHSN definition CDC/NHSN criteria Retrospective
cohort
81 45 81 NA






criteria of age ≥16
years and who were
mechanically ventilated
for ≥48 h
CDC/NHSN definition CDC/NHSN criteria Interrupted time
series analysis
1320 139 148 NA
[32] Australia 1 MICU, SICU 2009.05–
2011.01
All patients aged >18




(increases in FiO2 by
≥15 % or PEEP by
≥2.5 cm H2O lasting
≥2 days after stable
or decreasing FiO2 or
PEEP lasting ≥ 2 days.)
NA Retrospective
cohort









Table 1 Characteristics of studies included in the meta-analysis (Continued)
[33] USA 3 MICU, SICU 2006–2007 All patients aged >18




(increases in FiO2 by
≥15 % or positive
end-expiratory
pressure (PEEP) by
≥2.5 cm H2O lasting
≥2 days after stable
or decreasing FiO2





597 135 55 Age, sex, hospital, unit
type, and Charlson
comorbidity index
[34] USA 1 ICU 2009.07–
2013.12
Patients at least 18 years




support for at least 48 h,
and received a minimum




CDC/NHSN definition CDC/NHSN criteria Retrospective
cohort
216 31 64 NA
a,bStudy that comprised 2 separate groups within one article. cPatients with ventilator-associated pneumonia (VAP) were limited to four ICUs among all nine ICUs in the included study. NHSN National Healthcare Safety
Network, MICU medical intensive care unit, SICU surgical intensive care unit, CICU cardiac intensive care unit, VAP ventilator-associated pneumonia, VAE ventilator-associated events (including ventilator-associated conditions
(VAC), infection-related VAC (IVAC), possible VAP, and probable VAP), SAT/SBT spontaneous awakening trials/spontaneous breathing trials, PEEP positive end-expiratory pressure, FiO2 fraction of inspired oxygen, CDC Centers for









pooled sensitivity (p < 0.01) and negative predictive
value of VAC (p < 0.01), and pooled prevalence of
VAP (p = 0.01).
Discussion
In our systematic review, the pooled VAE prevalence
among patients who received mechanical ventilation in
the ICU, 13.8 %, was higher than the observed 11.9 %
pooled prevalence of VAP. This result is reasonable, be-
cause the VAE paradigm aims to identify a broader range
of ventilator-associated complications, including both in-
fectious complications (such as pneumonia, tracheitis,
and tracheobronchitis) and non-infectious complications
(such as atelectasis, pulmonary embolism, pulmonary
oedema, and ventilator-induced lung injury) [36]. In a
previous study VAP was estimated to be the most com-
mon complication, accounting for about 25–40 % of
VAE, followed by fluid overload at 20–40 %, ARDS at
10–20 %, and atelectasis at 10–15 % [37]. Theoretically,
by excluding non-infectious complications among VAE,
IVAC should be more representative of VAP, and its
prevalence should be closer to but still higher than VAP.
However, in our meta-analysis, the pooled prevalence of
IVAC was lower than that of VAP, and even in the









Heterogeneity Publication biasa Effect
modelI2 (%) P t value (Egger test) P
VAC
MV >0 day 17 68747 13.8 9.0, 18.6 99.8 <0.01 1.54 0.15 Random
MV ≥2 days 13 25935 20.1 9.6, 30.6 99.8 <0.01 0.53 0.60 Random
MV ≥3 days 5 19408 26.9 5.0, 48.8 99.9 <0.01 0.69 0.54 Random
MV ≥4 days 4 9349 30.7 −1.5, 62.9 99.9 <0.01 0.05 0.97 Random
MV ≥5 days 1 3028 77.0 75.5, 78.5 NA NA NA NA NA
IVAC
MV >0 day 14 55430 6.4 4.8, 8.1 99.0 <0.01 2.15 0.05 Random
MV ≥2 days 10 21558 9.6 5.8, 13.3 99.1 <0.01 1.22 0.26 Random
MV ≥3 days 3 15944 14.8 3.9, 25.7 99.7 <0.01 2.60 0.23 Random
MV ≥4 days 2 5885 20.4 4.0, 36.7 99.6 <0.01 NA NA Random
MV ≥5 days 1 3028 28.7 27.0, 30.0 NA NA NA NA NA
Possible VAP
MV >0 day 7 46820 1.1 0.5, 1.7 97.2 <0.01 0.98 0.37 Random
MV ≥2 days 4 16205 2.5 0.8, 4.1 98.7 <0.01 1.23 0.34 Random
MV ≥3 days 2 12916 4.5 −0.9, 10.0 99.3 <0.01 NA NA Random
MV ≥4 days 1 2857 8.5 7.0, 10.0 NA NA NA NA NA
MV ≥5 days 0 NA NA NA NA NA NA NA NA
Probable VAP
MV >0 day 8 47524 0.9 0.6, 1.2 91.7 <0.01 1.14 0.30 Random
MV ≥2 days 5 16642 1.6 0.8, 2.5 94.9 <0.01 1.05 0.37 Random
MV ≥3 days 2 12916 1.7 1.5, 1.9 0.0 0.378 NA NA Fixed
MV ≥4 days 1 2557 2.2 2.0, 3.0 NA NA NA NA NA
MV ≥5 days 0 NA NA NA NA NA NA NA NA
VAP
MV >0 day 10 17914 11.9 9.4, 14.4 99.5 <0.01 3.64 <0.01 Random
MV ≥2 days 10 12552 13.7 9.3, 18.1 99.5 <0.01 3.79 <0.01 Random
MV ≥3 days 2 6341 14.7 −9.2, 38.7 99.9 <0.01 NA NA Random
MV ≥4 days 2 5885 14.9 −8.6, 38.5 99.9 <0.01 NA NA Random
MV ≥5 days 1 3028 26.9 25.0, 29.0 NA NA NA NA NA
aEgger’s test was used to estimate publication bias in meta-analyses containing more than two individual studies. VAE ventilator-associated events including
ventilator-associated conditions (VAC), infection-related ventilator-associated conditions (IVAC), and possible ventilator-associated pneumonia (VAP), MV mechanical
ventilation, NA not available
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sensitivity analysis, both VAC and IVAC were lower than
VAP after limiting the evaluation to studies that used
stricter diagnostic criteria. This result indicates that VAE
surveillance might miss a certain number of cases of
VAP.
Actually, among the 11 studies included in our meta-
analysis that reported both VAC and VAP [19–22, 24–
26, 28, 31, 32, 34], the pooled sensitivity of VAC for the
detection of VAP was not satisfactory. Only 41.8 % of
cases of VAP could be identified by using the VAC
criteria; in other words, VAC surveillance missed
about 60 % of ventilated patients who developed
pneumonia. Similarly, the pooled PPV of VAC from
nine studies [19, 21, 22, 24–26, 28, 32, 34] also indi-
cated a poor capability for VAP detection. Only 23.2
% of patients who met the VAC criteria would be
diagnosed as having VAP. Even excluding the non-
infectious complications among VAE, the pooled sen-
sitivity and PPV of IVAC, possible VAP and probable
VAP for the detection of VAP were still low.
Most patients with VAP did not meet the VAE criteria,
mainly because they did not meet the requirements for
stable baseline mechanical ventilator settings or
threshold levels of worsening gas exchange. In a study
by Lilly et al., 70.8 % of patients with VAP did not have 2
days of stable oxygenation in the time frame required by
the VAE criteria [26]. Moreover, this percentage was
82.6 % in a study by Annop at al., and only 17.4 % for
insufficient levels of worsening gas exchange [35]. In
contrast, in the study by Klouwenberg at al. [28], among
VAP episodes that did not fulfil the criteria for VAE,
those with no baseline period of stability accounted for
only 24.0 % of the cohort, and those with insufficient
increase in ventilator settings accounted for 76.0 % of
the cohort. Similarly, in a study by Stoeppel et al., these
rates were 39.4 % for insufficient period of stability
followed by worsening oxygenation and 47.5 % for dur-
ation of respiratory deterioration less than 2 days [24].
Another explanation for the poor validity of VAE
criteria for identifying VAP is that VAE criteria do not
rely on chest radiography, which is the most sensitive
indicator of pathologically diagnosed VAP [38, 39]. On
the other hand, although the established diagnostic cri-
teria for VAP are widely clinically accepted and applied,
recent VAP criteria are seriously flawed in the subjectiv-
ity of clinical diagnosis, which might be another factor









Heterogeneity Publication biase Effect
modelI2 (%) P t value (Egger’s test) P
Sensitivity
VAC 11 1633a 41.8 17.7, 65.9 99.2 <0.01 −3.53 <0.01 Random
IVAC 6 1323a 36.3 14.4, 58.3 98.4 <0.01 −1.74 0.16 Random
Possible VAP 2 248a 14.4 10.1, 18.8 70.6 0.07 NA NA Fixed
Probable VAP 2 248a 1.6 0.1, 3.2 51.9 0.15 NA NA Fixed
Specificity
VAC 9 23112b 84.5 76.6, 92.4 99.8 <0.01 −1.50 0.18 Random
IVAC 6 14459b 94.0 91.4, 96.7 97.7 <0.01 −0.99 0.38 Random
Possible VAP 1 8325b 97.3 96.9, 97.6 NA NA NA NA NA
Probable VAP 1 8325b 99.3 99.1, 99.5 NA NA NA NA NA
Positive predictive value
VAC 9 3572c 23.2 12.6, 33.9 99.1 <0.01 1.25 0.25 Random
IVAC 5 1563c 47.2 16.1, 78.3 99.5 <0.01 0.63 0.57 Random
Possible VAP 1 243c 7.4 4.1, 10.7 NA NA NA NA NA
Probable VAP 1 62c 6.5 0.3, 12.6 NA NA NA NA NA
Negative predictive value
VAC 9 20927d 95.6 94.7, 96.5 98.2 <0.01 −7.30 <0.01 Random
IVAC 6 14211d 93.3 91.5, 95.0 99.1 <0.01 −3.89 0.02 Random
Possible VAP 1 8165d 99.2 99.0, 99.4 NA NA NA NA NA
Probable VAP 1 8346d 99.1 98.8, 99.3 NA NA NA NA NA
aNumber of patients with ventilator-associated pneumonia (VAP). bNumber of patients without VAP. cNumber of patients in the corresponding ventilator-
associated events (VAE) type. dNumber of patients in the corresponding non-VAE type. eEgger’s test was used to estimate publication bias in meta-analyses
containing more than two individual studies, NA not available
VAE include ventilator-associated conditions (VAC), infection-related ventilated-associated conditions (IVAC), possible VAP, and probable VAP
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affecting the consistency of detection results between
the two surveillance methods [40].
In our meta-analysis, although there were high rates of
pooled specificity and high NPV for the VAE paradigm,
the value of VAE for VAP detection was limited, given
that negative screens are caused not only by cases in
which the entity is absent, but also by those in which the
entity is missed or not clear. In fact the VAP diagnostic
criteria, which have been regarded as the gold standard
for screening tests, are not objective or specific criteria,
so high specificity or NPV for VAE does not indicate
that an acceptable proportion of cases of VAP were
detected by the screening test.
Some characteristics of the populations identified by
VAE and VAP surveillance also significantly differed.
Both VAE and VAP could prolong the length of ventila-
tion and hospital stay, but the risk intensity was different
in these two paradigms. By definition, VAE and VAP
should differ in ventilation duration, because VAP re-
quires the patient to receive mechanical ventilation for
more than 2 days, while at least 4 days are required for
VAE. However, interestingly, the pooled WMD of venti-
lation duration for VAE was about −3 days compared
with VAP. This result implies that patients with VAE
who did not meet VAP criteria such as fluid overload,
Fig. 2 The receiver operating characteristic (ROC) curves for
ventilator-associated conditions (VAC) and infection-related VAC
(IVAC) for the detection of ventilator-associated pneumonia (VAP).
Scatter points were plotted by the pooled sensitivity and 1-specificity
of each included study and trend lines were fitted by the log function.
ROCs were not plotted for possible and probable VAP, because studies
that provided original sensitivity and specificity data were scarce












Heterogeneity Publication biasc Effect
modelI2 (%) P t value (Egger’s test) P
VAC
Age 1 37 121 0.00a −5.89, 5.89 NA NA NA NA NA
Sex (male/female) 3 551 255 0.85b 0.59, 1.21 20.60 0.28 −2.68 0.24 Fixed
APACHE 1 387 83 5.00a −1.67, 11.67 NA NA NA NA NA
Ventilated duration (days) 3 569 299 −2.79a −4.79, −0.80 0.00 0.81 −3.39 0.18 Fixed
Death in hospital 5 857 393 1.49b 1.11, 2.01 53.10 0.07 −1.37 0.27 Fixed
Length of stay (days)
In hospital 4 1244 329 −4.27a −7.00, −1.55 47.40 0.13 0.20 0.94 Fixed
In ICU 2 802 81 −0.64a −5.84, 4.55 74.50 0.05 NA NA Random
IVAC
Age 1 31 121 0.00a −6.63, 6.63 NA NA NA NA NA
Sex (male/female) 3 406 268 1.05b 0.70, 1.59 0.00 0.46 0.29 0.82 Fixed
APACHE 1 344 83 4.00a −2.53, 10.53 NA NA NA NA NA
Ventilated duration (days) 2 384 248 −2.89a −5.58, −0.20 0.00 0.80 NA NA Fixed
Death in hospital 4 446 423 1.76b 1.23, 2.52 0.00 0.77 0.50 0.67 Fixed
Length of stay (days)
In hospital 2 384 248 −5.86a −9.46, −2.25 0.00 0.92 NA NA Fixed
In ICU 0 0 0 NA NA NA NA NA NA NA
aEstimate refers to weighted mean difference (WMD). bEstimate refers to odds ratio (OR). cEgger’s test was used to estimate publication bias in meta-analyses
containing more than two individual studies. VAE ventilator-associated conditions (including ventilator-associated conditions (VAC), infection-related ventilated-
associated conditions (IVAC), possible ventilator-associated pneumonia (VAP), and probable VAP), APACHE acute physiology and chronic health evaluation, NA
not available
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ARDS, and atelectasis, tended to receive a shorter dur-
ation of mechanical ventilation. Similarly, the mean hos-
pital LOS for VAC and IVAC was about 4–6 days
shorter than that of VAP. These differences may have
been due to discrepancies in the severity of comorbidi-
ties and differences in the timing of extubation.
Additionally, the in-hospital mortality of VAC and
IVAC was approximately twofold higher than that of
VAP. In fact, a sustained decrease in oxygenation is an
independent risk factor for mortality in ventilated
patients [41], and thus, higher mortality associated with
VAE may due to the VAE criteria aiding in the detection
of more severe patients with poorer oxygenation [20].
Only patients with complications severe enough to merit
the threshold levels of worsening gas exchange met the
VAE criteria, whereas patients with slight worsening of
gas exchange could still be diagnosed with VAP [34].
Indeed, about 60 % of patients diagnosed with VAP did
not meet the VAE criteria in our meta-analysis.
Overall, we found that patients’ duration of ventilation
and hospital stay were shorter in the VAE paradigm than
in the VAP paradigm, while in-hospital mortality was
higher in the VAE paradigm than in the VAP paradigm.
In other words, the characteristics of patients identified
by VAP surveillance were not accurately reflected by
VAE surveillance. Confounding complications in VAE
cases could have an influence on the significance of risk
factors. For example, ARDS was the most common com-
plication in VAE (46.8 %) in the study of Lilly et al. [26]
while it only accounted for 16.4 % of patients with VAE
in the study of Boyer et al. [21]. Consequently, the OR
of in-hospital death for VAE compared with VAP in the
former study was 1.50 (95 % CI 0.88 ~ 2.56) with no
statistical difference, whereas it was 2.29 (95 % CI
1.19 ~ 4.43) reflecting a statistical difference in the
latter study. The difference in distributions of compli-
cations may affect the population characteristics of VAE
surveillance, which aims to identify a broader spectrum of
complications of mechanical ventilation.
VAE surveillance has several advantages. First, VAE
diagnosis is less time-consuming than traditional VAP
diagnosis. The VAE paradigm was designed to rely on ob-
jective measures that can be easily assessed by profes-
sionals in the detection of infection. A study conducted in
two hospitals indicated that VAE reviewers required 12 h
to manually diagnose 400 ventilated patients, while the
traditional VAP reviewer required 260 hours [34]. Further-
more, objective measures can be easily coded into com-
puterized programmes. Consequently, software-based
automatic data collection processes can further reduce the
time needed for VAE identification. In a previous study,
automatic VAE surveillance required only 1 minute to as-
sess 110 patients, compared to 60.7 minutes using manual
surveillance [42].
Second, the VAE paradigm maximizes the objectivity
of surveillance to improve comparability [10]. Quantita-
tive measures of VAE are commonly available in every
ICU; thus, the objective criteria enable different institu-
tions to compare their rates with greater confidence,
such that differences in rates reflect differences in pa-
tients and processes of care rather than subjective and
unquantifiable surveillance biases.
Third, including a broader spectrum of complications is
beneficial to identifying a population of patients with ser-
ious complications who have not been acknowledged pre-
viously [2]. In fact, the VAE paradigm is able to identify
not only patients with complications of mechanical venti-
lation but also those with severe respiratory compromise
or progressive underlying disease, despite optimal care.
Therefore, the broader spectrum is beneficial to monitor-
ing critically ill patients in the ICU, making it possible to
prevent severe complications at an early stage.
Strengths of our study include the quantitative
methodology of the systematic review, a large sample
size for estimating the prevalence of each type of
VAE, and the assessment of consistency between VAE
and VAP surveillance. However, our meta-analysis
also has limitations. First, heterogeneity is a common
problem for meta-analyses of observational studies,
particularly those that involve proportions [43–45].
We attempted to explain heterogeneity by performing
subgroup analyses, but after an exploration of the fac-
tors that were likely to contribute to the variation,
such as study design and population characteristics,
the heterogeneity remained unexplained. Although ob-
jective measures were used as the criteria for VAE
monitoring, they were implemented independently in
different hospitals and ICUs. Therefore, it is difficult
to ensure that all surveillance activities are homoge-
neous in clinical practice. These constraints and
variations in setting, such as patients’ baseline charac-
teristics, data collection methods, and surveillance
systems, may account at least in part for the signifi-
cant heterogeneity observed [28].
Second, not every study reported prevalence or the
original number of cases of VAE within each ventilation
duration group, which is why the number of included
studies within each ventilation duration sub-group was
not equal, particularly for the small number of studies in
groups with MV ≥3 days, MV ≥4 days, and MV ≥5 days.
The insufficient number of studies included in these
groups led to an unstable pooled prevalence with a
broader 95 % CI in the meta-analysis; even 95 % CIs in
which the lower limit was negative were observed in sev-
eral groups in our study. Therefore, the results in these
groups should be interpreted with caution, and more
high-quality studies with standardized ventilation dur-
ation groups are needed in the future.
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Third, we did not conduct sub-group analysis in differ-
ent types of ICU because of insufficient sub-group data
within each type. The type of ICU type be a significant
confounding factor affecting the prevalence and popula-
tion characteristics of patients with VAE and VAP [26,
30]. Although the studies included in the meta-analysis
reported their own ICU type, most provided the overall
data from mixed ICU types rather than the sub-group
data for each type. Consequently, it was difficult to sep-
arate total data into sub-group data according to ICU
type in most included studies.
Finally, not all studies in our meta-analysis used the
same diagnostic criteria. We included three studies that
did not strictly meet CDC/NHSN criteria for VAE. A
multicentre study in France slightly adapted the VAE
definition, taking into account the change in PaO2/FiO2
with regard to the level of PEEP as a more reliable cri-
terion for the assessment of worsening oxygenation [22].
Two studies used an early definition of VAE prior to the
implementation of VAE surveillance by the NHSN in
January 2013 [33, 34]. These early studies diagnosed
VAE using looser criteria relative to the CDC/NHSN
definition. In addition, our meta-analysis contains five
studies that applied stricter VAP diagnostic criteria with
quantitative culture of specimens [19, 21, 24, 28, 35].
After limiting the meta-analysis to these studies using
stricter diagnostic criteria, the pooled estimates of
each VAE type and of VAP changed, but these
changes have limited effects on the relationship be-
tween VAE and VAP: the VAE paradigm still missed a
certain number of cases of VAP, in-hospital mortality
was still higher in patients with VAE than with VAP,
and ventilation duration was still shorter in patients
with VAE than with VAP.
Conclusions
Overall, the findings of the present study indicate that
VAE surveillance may not be suitable for identifying
patients with VAP. As each surveillance paradigm has its
own advantages, we suggest that traditional VAP surveil-
lance should not be replaced entirely by VAE surveil-
lance, but rather for both VAE and VAP surveillance to
be carried out in tandem according to the specific condi-
tions of each hospital and ICU.
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